News Article
Novo Nordisk trims 11% of workforce to refocus on diabetes and obesity core
Danish multinational pharmaceutical company Novo Nordisk’s September restructuring marks its largest organisational reset in decades. The Denmark-based group is in the process of eliminating around 9,000 of 78,400 positions (c. 5,000 in Denmark) as it seeks to simplify decision-making, free up capital and defend leadership in the increasingly crowded GLP-1 diabetes-and-obesity arena.
With headcount having risen 73 % since 2020, new CEO Mike Doustdar frames the move as “evolving with the market” rather than retrenchment. Implementation has begun, subject to local labour consultations.
The workforce reduction is aimed at unlocking DKK 8bn (€1.07bn) in annual savings, funding diabetes–obesity growth initiatives and offsetting rising complexity
The restructuring looks to position Novo Nordisk to fund high-priority assets and manufacturing scale, with success relying on on converting savings into accelerated launches and defending its GLP-1 share.
